Andere Sprachen INVO Bioscience, Inc.

Aktien

A3EJLW

US44984F4019

INVO

Verzögert Nasdaq Andere Börsenplätze 22:00:00 08.05.2024			% 5 Tage	% 1. Jan.
0.93 ^USD	0.00%		-7.00%	-31.11%

16.04.	INVO Bioscience, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
2023	NAYA Biosciences Inc. gibt die Veröffentlichung neuer Daten für seinen gegen CD38 gerichteten Flex-NK Bispecific Antibody im Blood Journal der American Society of Hematology bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Exploring Emerging Companies with Key Developments Garnering Attention: INBS, INVO, VTAK, RCAT, GCTK	22.04.
Top Premarket Decliners	18.04.
Sector Update: Health Care Stocks Retreating Late Afternoon	17.04.
Top Midday Gainers	17.04.
Traders Digest Earnings After Rate-Driven Losses, US Equity Futures Rebound Slightly	17.04.
Top Premarket Gainers	17.04.
INVO Reports Fourth Quarter and Full Year 2023 Financial Results	16.04.
INVO Bioscience : Reports Fourth Quarter and Full Year 2023 Financial Results - Form 8-K	16.04.
INVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16.04.
INVO Bioscience, Inc. announced that it has received $0.5 million in funding from FirstFire Capital Management LLC	08.04.
INVO Bioscience, Inc. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC	05.04.
INVO Bioscience : Private Placement - Form 8-K	01.04.
Certain Options of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	09.02.
Certain Warrants of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	09.02.
Certain Common Stock of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	09.02.
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors	17.01.
INVO Bioscience, Inc. announced that it expects to receive $5 million in funding from NAYA Biosciences Inc.	29.12.
INVO Bioscience : Submission of Matters to a Vote of Security Holders - Form 8-K	28.12.
NAYA Biosciences Announces Publication Of New Data For Its CD38-Targeted Flex-NK Bispecific Antibody in The American Society of Hematology s Blood Journal	12.12.
NAYA Biosciences Inc. Announces Publication of New Data for its CD38-targeted Flex-NK Bispecific Antibody in the American Society of Hematology's Blood Journal	11.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen INVO Bioscience, Inc.

Aktien

A3EJLW

US44984F4019

INVO

Andere Sprachen

Filter